Managing Pneumonia Due to Rare Non-Fermenting Gram-Negative Bacteria: Epidemiology, Risk Factors and Therapeutic Strategies
Antibiotics · 04.05.2026 · 15 (5) · 465
DOI: 10.3390/antibiotics15050465 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 04.05.2026. Verfasst von Alessandro Capone und 8 weiteren Autor:innen. Beteiligte Einrichtung: Systemic and Immune Depression-Associated Infections Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, 00149 Rome, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.
Abstract (Originalsprache)
Pneumonia remains a leading cause of morbidity and mortality worldwide, with bacterial pathogens contributing significantly to its burden. While Pseudomonas aeruginosa and Acinetobacter baumannii complex are well-recognized non-fermenting Gram-negative bacteria (NFGNB) causing severe pneumonia, particularly in healthcare settings, an expanding array of other, rarer NFGNB species is increasingly implicated. These species include, but are not limited to, Achromobacter spp., Ochrobactrum spp., Burkholderia spp., Aeromonas spp., Roseomonas spp., Elizabethkingia spp., Chryseobacterium spp. Alcaligenes spp., Ralstonia spp., Cupriavidus spp., Sphingomonas spp., Rhizobium spp., Empedobacter spp., and Brevundimonas spp. In this article we aim to provide a focused review of the contemporary epidemiology and specific risk factors for pneumonia caused by this diverse group of rare NFGNB, explicitly excluding P. aeruginosa, Stenotrophomonas maltophilia, and A. baumannii. We seek to delineate the emerging patterns of pneumonia associated with Achromobacter spp., Burkholderia spp., Aeromonas spp., Roseomonas spp., Elizabethkingia spp., Pandoraea spp., Sphingomonas spp., and K. gyiorum. Moreover, we discuss antimicrobial treatment strategies for pneumonia caused by rarer NFGNB including Ochrobactrum spp., Chryseobacterium spp., Alcaligenes spp., Ralstonia spp., Cupriavidus spp., Rhizobium spp., Empedobacter spp., and Brevundimonas spp. A deeper understanding of these specific epidemiological trends and risk factors is important for guiding precise diagnostic approaches, informing antimicrobial stewardship programs, and developing targeted infection prevention and control strategies with the aim of mitigating the impact of these challenging pathogens in the clinical setting.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Systemic and Immune Depression-Associated Infections Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, 00149 Rome, Italy.
- Microbiology and Biobank Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, 00149 Rome, Italy.
ORCID-Profile: Valentina Antonelli, Claudia Rotondo, Carla Fontana, Stefania Cicalini
Förderung
- Ministero della Salute
Zitieren
APA
Capone, A., Gavaruzzi, F., Antonelli, V., Rotondo, C., Al Moghazi, S., Caraffa, E., Chinello, P., Fontana, C., & Cicalini, S. (2026). Managing Pneumonia Due to Rare Non-Fermenting Gram-Negative Bacteria: Epidemiology, Risk Factors and Therapeutic Strategies. Antibiotics, 15(5), 465. https://doi.org/10.3390/antibiotics15050465
Vancouver
Capone A, Gavaruzzi F, Antonelli V, Rotondo C, Al Moghazi S, Caraffa E, et al. Managing Pneumonia Due to Rare Non-Fermenting Gram-Negative Bacteria: Epidemiology, Risk Factors and Therapeutic Strategies. Antibiotics. 2026;15(5):465. doi:10.3390/antibiotics15050465
BibTeX
@article{Capone2026,
author = {Capone, Alessandro and Gavaruzzi, Francesca and Antonelli, Valentina and Rotondo, Claudia and Al Moghazi, Samir and Caraffa, Emanuela and Chinello, Pierangelo and Fontana, Carla and Cicalini, Stefania},
title = {Managing Pneumonia Due to Rare Non-Fermenting Gram-Negative Bacteria: Epidemiology, Risk Factors and Therapeutic Strategies},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {5},
pages = {465},
doi = {10.3390/antibiotics15050465}
}
EUVIMED